STATESVILLE – Kewaunee Scientific’s order backlog rose to $169 million during its fiscal first quarter as sales declined 6.7% from a year earlier.
The laboratory-furniture manufacturer reported $66.32 million in sales for the quarter ended July 31, down from $71.10 million in the same period a year earlier. Net earnings attributable to Kewaunee fell to $1.71 million from $3.09 million, and diluted earnings per share declined to $0.58 from $1.04.
Backlog increased from $165.9 million at the end of April but remained below the $205 million reported on July 31, 2025.
Sales in Kewaunee’s Lab Products Group declined 6.4% to $50.87 million. The company attributed the decrease primarily to lower demand in the domestic laboratory-construction market, particularly life sciences, while citing a stronger education market and operating efficiencies as offsets.
International sales decreased 7.8% to $15.45 million. The segment’s net earnings nevertheless increased 23.5% to $794,000, while segment EBITDA, a non-GAAP measure, rose 13.9% to $1.20 million. Kewaunee said a greater mix of higher-margin projects drove the improvement.
Long-term debt totaled $39.38 million at quarter-end, including $25.53 million tied to a sale-leaseback financing arrangement for the company’s Statesville headquarters and manufacturing facilities. Excluding that obligation, long-term debt declined to $13.84 million from $15.09 million at the end of April.
President and CEO Thomas D. Hull III said quoting activity remained strong, although project award and release timelines were extended amid economic and geopolitical uncertainty.
Kewaunee Scientific is headquartered in Statesville and operates three manufacturing facilities there. The company designs and manufactures laboratory, healthcare and technical furniture, and its shares trade on the Nasdaq Global Market under the ticker KEQU.
